

October 24, 2024

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549-3720

Attention: Alan Campbell

**Re: Athira Pharma, Inc.**

**Registration Statement on Form S-3**

**Filed October 21, 2024**

**(File No. 333-282738)**

**Acceleration Request**

**Requested Date: October 28, 2024**

**Requested Time: 4:00 P.M. Eastern Daylight Time,  
or as soon thereafter as practicable**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Athira Pharma, Inc. (the “**Company**”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-282738) (the “**Registration Statement**”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Michael Nordtvedt at (206) 883-2524 or Bryan King at (206) 883-2535.

*[Signature page follows]*

---

Sincerely,

ATHIRA PHARMA, INC.

/s/ Robert Renninger

Robert Renninger  
*Vice President of Finance*

Enclosures

cc: Mark Litton, Athira Pharma, Inc.  
Mark Worthington, Athira Pharma, Inc.  
Michael Nordtvedt, Wilson Sonsini Goodrich & Rosati P.C.  
Bryan D. King, Wilson Sonsini Goodrich & Rosati P.C.

---